FDMT Stock: 4D Molecular Therapeutics, Inc. Stock Price, Analysis & Insights
Get live fdmt stock price $9.21, comprehensive 4D Molecular Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time fdmt stock data and investment insights.
Loading chart...
Company Overview
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Company Information
- CEO
- David H. Kirn
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 227
Contact Information
- Address
- 5858 Horton Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 2.95)
Business Model & Strategy
4D Molecular Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO David H. Kirn, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
4D Molecular Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 430.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, 4D Molecular Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating 4D Molecular Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for 4D Molecular Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for 4D Molecular Therapeutics, Inc.
- ⚠Investors should consider how 4D Molecular Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
430.13M
P/E Ratio
-2.46
Beta
2.95
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 430.13M market capitalization
- Trading Volume: 3.30M shares traded today
- Price Range: 52-week range of $2.23 - $12.34
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 430.13M, the company represents a significant player in its market. The stock is currently trading at $9.21 with a negativedaily change of 20.05%.
The company's 227 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -2.46, beta of 2.95, and 52-week price range from $2.23 to $12.34when evaluating investment opportunities.
Why Invest in 4D Molecular Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under David H. Kirn
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.